Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Jan 15, 2023; 15(1): 1-18
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.1
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.1
Clinical trials number | Study type | Agent(s) | Local regional therapy | Estimated enrollment | Primary endpoint |
chiCTR2100044057 | Phase II | Camrelizumab + Bevacizumab | Microwave Ablation | 30 | PFS |
chiCTR2100046533 | Prospective | Apatinib + Camrelizumab | TACE | 37 | PFS |
NCT05162898 | Prospective | Toripalimab + Lenvatinib | Radiofrequency Ablation | 90 | PFS |
NCT05010434 | Phase II | Sintilimab + Bevacizumab | Radiofrequency Ablation | ORR | |
NCT05444478 | Prospective | Lenavatinib | Microwave Ablation | 274 | 3-yr PFS% |
NCT05277675 | Prospective | Tislelizumab/Sintilimab + Lenvatinib/Bevacizumab | Radiofrequency Ablation | 160 | 1-yr PFS% |
NCT05162898 | Prospective | Toripalimab + Lenvatinib | Radiofrequency ablation | 90 | RFS |
NCT04663035 | Phase II | Tislelizumab | Ablation | 120 | 1-yr PFS% |
NCT05355155 | Phase II | Bevacizumab + Biosimilar IBI305 | - | 15 | ORR |
NCT05103904 | Phase II | Lenvatinib | - | 19 | ORR |
NCT04615143 | Prospective | Tislelizumab/Tislelizumab + Levatinib | - | 80 | PFS |
NCT04564313 | Phase I | Camrelizumab | - | 20 | ORR |
NCT04237740 | Phase III | Relenvatinib | - | 40 | 3-yr PFS% |
NCT04204850 | Phase II | Cabozantinib | 20 | DCR |
- Citation: Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18
- URL: https://www.wjgnet.com/1948-5204/full/v15/i1/1.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i1.1